Pan cytokeratin antibody

Briefly, we collected the NPs from two patients with clinically significant responses to LNI (the cross-sectional area of the polyps in endoscopic images was reduced by 60–100% after treatment) (Fig. 2). After their NPs were separated, the fibroblasts were isolated and cultured to enable subsequent cell experiments. The NPs were obtained during sinonasal surgery and were subsequently processed into single-cell suspensions using a gentle MACS dissociator (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), which is a specialized machine for processing human nasal mucosa into single-cell suspensions. Furthermore, we sorted the nasal polyp-derived fibroblasts (NPDFs) from the single-cell suspensions. On the basis of the protocol of the EasySep Human-Positive Selection Kit II (STEMCELL Technologies Inc., Vancouver, Canada), the samples were placed into a magnet and then incubated for the sorting process. Next, we sorted and purified the NPDFs using flow cytometry (BD FACS Canto II, BD Biosciences, San Jose, CA, USA) with fluorochrome-conjugated antibody clones, including the anti-human fibroblast antibody (anti-vimentin antibody for human, Abcam, Cambridge, MA, USA) and pan-cytokeratin antibody (Santa Cruz Biotechnology), which was considered the control. After sorting, we further employed flow cytometry to confirm the isolated cells with anti-vimentin antibodies.